134 related articles for article (PubMed ID: 29268508)
1. Volume doubling time of lung adenocarcinomas considering epidermal growth factor receptor mutation status of exon 19 and 21: three-dimensional volumetric evaluation.
Zhang R; Chen B; Zhou Y; Zhou P; Jin J; Zhao L; Li W
J Thorac Dis; 2017 Nov; 9(11):4387-4397. PubMed ID: 29268508
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor mutations: effect on volume doubling time of non-small-cell lung cancer patients.
Nakamura R; Inage Y; Tobita R; Mori K; Numata T; Yanai H; Endo T; Ohtani H; Satoh H; Yuzawa K; Koizumi M; Ueki H
J Thorac Oncol; 2014 Sep; 9(9):1340-4. PubMed ID: 24481317
[TBL] [Abstract][Full Text] [Related]
3. Volume Doubling Times of Lung Adenocarcinomas: Correlation with Predominant Histologic Subtypes and Prognosis.
Park S; Lee SM; Kim S; Lee JG; Choi S; Do KH; Seo JB
Radiology; 2020 Jun; 295(3):703-712. PubMed ID: 32228296
[TBL] [Abstract][Full Text] [Related]
4. CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the Lung.
Ozkan E; West A; Dedelow JA; Chu BF; Zhao W; Yildiz VO; Otterson GA; Shilo K; Ghosh S; King M; White RD; Erdal BS
AJR Am J Roentgenol; 2015 Nov; 205(5):1016-25. PubMed ID: 26496549
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes.
Lee HJ; Kim YT; Kang CH; Zhao B; Tan Y; Schwartz LH; Persigehl T; Jeon YK; Chung DH
Radiology; 2013 Jul; 268(1):254-64. PubMed ID: 23468578
[TBL] [Abstract][Full Text] [Related]
6. The impact of histology and ground-glass opacity component on volume doubling time in primary lung cancer.
Obayashi K; Shimizu K; Nakazawa S; Nagashima T; Yajima T; Kosaka T; Atsumi J; Kawatani N; Yazawa T; Kaira K; Mogi A; Kuwano H
J Thorac Dis; 2018 Sep; 10(9):5428-5434. PubMed ID: 30416791
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas.
Liu WS; Zhao LJ; Pang QS; Yuan ZY; Li B; Wang P
Med Oncol; 2014 Jan; 31(1):771. PubMed ID: 24248816
[TBL] [Abstract][Full Text] [Related]
8. Prediction of the stage shift growth of early-stage lung adenocarcinomas by volume-doubling time.
Tang EK; Wu YJ; Chen CS; Wu FZ
Quant Imaging Med Surg; 2024 Jun; 14(6):3983-3996. PubMed ID: 38846271
[TBL] [Abstract][Full Text] [Related]
9. Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma.
Cao Y; Xu H; Liao M; Qu Y; Xu L; Zhu D; Wang B; Tian S
Int J Clin Oncol; 2018 Apr; 23(2):249-257. PubMed ID: 28988295
[TBL] [Abstract][Full Text] [Related]
10. PET standardized uptake values of primary lung cancer for comparison with tumor volume doubling times.
Siddique M; Yip R; Henschke CI; Yankelevitz DF
Clin Imaging; 2021 May; 73():146-150. PubMed ID: 33418311
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of volume doubling time in surgically resected non-small cell lung cancer.
Mackintosh JA; Marshall HM; Yang IA; Bowman RV; Fong KM
Respirology; 2014 Jul; 19(5):755-62. PubMed ID: 24797504
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
Naidoo J; Sima CS; Rodriguez K; Busby N; Nafa K; Ladanyi M; Riely GJ; Kris MG; Arcila ME; Yu HA
Cancer; 2015 Sep; 121(18):3212-3220. PubMed ID: 26096453
[TBL] [Abstract][Full Text] [Related]
13. Computed tomography characteristics of lung adenocarcinomas with epidermal growth factor receptor mutation: A propensity score matching study.
Suh YJ; Lee HJ; Kim YJ; Kim KG; Kim H; Jeon YK; Kim YT
Lung Cancer; 2018 Sep; 123():52-59. PubMed ID: 30089595
[TBL] [Abstract][Full Text] [Related]
14. Clinicoradiological features associated with epidermal growth factor receptor exon 19 and 21 mutation in lung adenocarcinoma.
Zhao FN; Zhao YQ; Han LZ; Xie YS; Liu Y; Ye ZX
Clin Radiol; 2019 Jan; 74(1):80.e7-80.e17. PubMed ID: 30591175
[TBL] [Abstract][Full Text] [Related]
15. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
16. CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.
Liu Y; Kim J; Qu F; Liu S; Wang H; Balagurunathan Y; Ye Z; Gillies RJ
Radiology; 2016 Jul; 280(1):271-80. PubMed ID: 26937803
[TBL] [Abstract][Full Text] [Related]
17. Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma.
Hsu JS; Huang MS; Chen CY; Liu GC; Liu TC; Chong IW; Chou SH; Yang CJ
J Thorac Imaging; 2014 Nov; 29(6):357-63. PubMed ID: 25303964
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutations are more frequent in well-differentiated than in poor-differentiated lung adenocarcinomas.
Liu Y; Xu ML; Zhong HH; Heng WJ; Wu BQ
Pathol Oncol Res; 2008 Dec; 14(4):373-9. PubMed ID: 18985444
[TBL] [Abstract][Full Text] [Related]
19. Volume and mass doubling times of persistent pulmonary subsolid nodules detected in patients without known malignancy.
Song YS; Park CM; Park SJ; Lee SM; Jeon YK; Goo JM
Radiology; 2014 Oct; 273(1):276-84. PubMed ID: 24927472
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of epidermal growth factor receptor mutations and its clinico-pathologic characteristics of the primary lung adenocarcinoma in Xinjiang Uighur Autonomous Region].
Ma XM; Cao YZ; Ji WL; Zhao F; Fang XZ
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):663-666. PubMed ID: 29263509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
